Clinical Trials Directory

Trials / Completed

CompletedNCT02044445

Is the IVF Outcome Dependent on the Time Interval Between hCG Administration and Oocyte Retrieval?

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
154 (actual)
Sponsor
Aristotle University Of Thessaloniki · Academic / Other
Sex
Female
Age
20 Years – 43 Years
Healthy volunteers
Not accepted

Summary

During controlled ovarian hyperstimulation (COH), human chorionic gonadotrophin (hCG) is administered to trigger the final follicular maturation before oocyte retrieval, in an attempt to mimic the physiologic effects of LH. The hCG is administered when more than three follicles ≥17mm in mean diameter have developed. The time interval between hCG administration and oocyte retrieval is of critical importance since the time after luteinizing stimulus is a period of intense processes including the start of luteinization, expansion of cumulus cells and oocyte meiotic maturation. The commonly practiced hCG administration time of 33 to 36 h in most IVF cycles aims to avoiding spontaneous ovulation before oocyte retrieval. However, several studies have shown that significantly more high quality embryos have been obtained with a prolonged hCG-to-oocyte interval of 38 h. It has been hypothesized that longer interval would be beneficial in improving oocyte quality and achieving optimal maturation. Currently there are no data on the effect of the time interval between hCG administration and oocyte retrieval on IVF outcome in GnRH antagonist cycles. The aim of this study is to determine whether there is any difference in in vitro fertilization outcome when oocyte retrieval takes place at 36 h or 38 h following hCG administration

Conditions

Interventions

TypeNameDescription
PROCEDUREOocyte retrieval will be performed 36 h or 38 h after hCG administrationOocyte retrieval will be performed 36 h or 38 h after hCG administration

Timeline

Start date
2009-11-01
Primary completion
2013-12-01
First posted
2014-01-24
Last updated
2014-05-28

Locations

1 site across 1 country: Greece

Source: ClinicalTrials.gov record NCT02044445. Inclusion in this directory is not an endorsement.